Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.

Tytuł:
Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage.
Autorzy:
Gerner ST; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Kuramatsu JB; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Sembill JA; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Sprügel MI; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Hagen M; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Knappe RU; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Endres M; Department of Neurology (M.E., K.G.H., J. Sobesky, S.Z.), Charité-Universitätsmedizin Berlin, Germany.; Center for Stroke Research Berlin, Berlin, Germany (M.E., K.G.H., J. Sobesky, J. Schurig, M.B.).; German Centre for Cardiovascular Research (DZHK), Oudenarder Straße, Berlin (M.E.).; German Center for Neurodegenerative Diseases (DZNE), partner site Berlin (M.E.).
Haeusler KG; Department of Neurology (M.E., K.G.H., J. Sobesky, S.Z.), Charité-Universitätsmedizin Berlin, Germany.; Center for Stroke Research Berlin, Berlin, Germany (M.E., K.G.H., J. Sobesky, J. Schurig, M.B.).; Department of Neurology, University of Würzburg, Germany (K.G.H., J.V., W.M., P.K., A.-L.S.).
Sobesky J; Department of Neurology (M.E., K.G.H., J. Sobesky, S.Z.), Charité-Universitätsmedizin Berlin, Germany.; Center for Stroke Research Berlin, Berlin, Germany (M.E., K.G.H., J. Sobesky, J. Schurig, M.B.).
Schurig J; Center for Stroke Research Berlin, Berlin, Germany (M.E., K.G.H., J. Sobesky, J. Schurig, M.B.).
Zweynert S; Department of Neurology (M.E., K.G.H., J. Sobesky, S.Z.), Charité-Universitätsmedizin Berlin, Germany.
Bauer M; Center for Stroke Research Berlin, Berlin, Germany (M.E., K.G.H., J. Sobesky, J. Schurig, M.B.).
Vajkoczy P; Department of Neurosurgery (P.V.), Charité-Universitätsmedizin Berlin, Germany.
Ringleb PA; Department of Neurology, Heidelberg University Hospital, Germany (P.A.R., J.C.B., T.R.).
Purrucker JC; Department of Neurology, Heidelberg University Hospital, Germany (P.A.R., J.C.B., T.R.).
Rizos T; Department of Neurology, Heidelberg University Hospital, Germany (P.A.R., J.C.B., T.R.).
Volkmann J; Department of Neurology, University of Würzburg, Germany (K.G.H., J.V., W.M., P.K., A.-L.S.).
Müllges W; Department of Neurology, University of Würzburg, Germany (K.G.H., J.V., W.M., P.K., A.-L.S.).
Kraft P; Department of Neurology, University of Würzburg, Germany (K.G.H., J.V., W.M., P.K., A.-L.S.).
Schubert AL; Department of Neurology, University of Würzburg, Germany (K.G.H., J.V., W.M., P.K., A.-L.S.).
Erbguth F; Department of Neurology, Community Hospital Nuremberg, Germany (F.E., M.N.).
Nueckel M; Department of Neurology, Community Hospital Nuremberg, Germany (F.E., M.N.).
Schellinger PD; Department of Neurology and Neurogeriatry (P.D.S., J.G.).
Glahn J; Department of Neurology and Neurogeriatry (P.D.S., J.G.).
Knappe UJ; Department of Neurosurgery, Johannes Wesling Medical Center Minden, University Clinic Ruhr University Bochum, Germany (U.J.K.).
Fink GR; Department of Neurology, University of Cologne, Germany (G.R.F. C.D., H. Stetefeld).
Dohmen C; Department of Neurology, University of Cologne, Germany (G.R.F. C.D., H. Stetefeld).; Department of Neurology, LVR Klinik Bonn, Germany (C.D.).
Stetefeld H; Department of Neurology, University of Cologne, Germany (G.R.F. C.D., H. Stetefeld).
Fisse AL; Department of Neurology, University of Münster, Germany (A.L.F., J.M.).
Minnerup J; Department of Neurology, University of Münster, Germany (A.L.F., J.M.).
Hagemann G; Department of Neurology, Community Hospital Helios Klinikum Berlin-Buch, Germany (G.H., F.R.).
Rakers F; Department of Neurology, Community Hospital Helios Klinikum Berlin-Buch, Germany (G.H., F.R.).
Reichmann H; Department of Neurology, University of Dresden, Germany (H.R., H. Schneider, J. Rahmig).; Department of Neurology, Klinikum Augsburg, Germany (H. Schneider).
Schneider H; Department of Neurology, University of Dresden, Germany (H.R., H. Schneider, J. Rahmig).
Rahmig J; Department of Neurology, University of Dresden, Germany (H.R., H. Schneider, J. Rahmig).
Ludolph AC; Department of Neurology, University of Ulm, Germany (A.C.L., S. Stösser, H.N.).
Stösser S; Department of Neurology, University of Ulm, Germany (A.C.L., S. Stösser, H.N.).
Neugebauer H; Department of Neurology, University of Ulm, Germany (A.C.L., S. Stösser, H.N.).
Röther J; Department of Neurology, Community Hospital Asklepios Klinik Hamburg Altona, Germany (J. Röther, P.M.).
Michels P; Department of Neurology, Community Hospital Asklepios Klinik Hamburg Altona, Germany (J. Röther, P.M.).
Schwarz M; Department of Neurology, Community Hospital Klinikum Dortmund, Germany (M.S., G.R.).
Reimann G; Department of Neurology, Community Hospital Klinikum Dortmund, Germany (M.S., G.R.).
Bäzner H; Department of Neurology, Community Hospital Klinikum Stuttgart, Germany (H.B., H. Schwert).
Schwert H; Department of Neurology, Community Hospital Klinikum Stuttgart, Germany (H.B., H. Schwert).
Claßen J; Department of Neurology, University of Leipzig, Germany (J.C., D.M.).
Michalski D; Department of Neurology, University of Leipzig, Germany (J.C., D.M.).
Grau A; Department of Neurology, Community Hospital Klinikum der Stadt Ludwigshafen am Rhein, Germany (A. Grau, F.P., C.U.).
Palm F; Department of Neurology, Community Hospital Klinikum der Stadt Ludwigshafen am Rhein, Germany (A. Grau, F.P., C.U.).
Urbanek C; Department of Neurology, Community Hospital Klinikum der Stadt Ludwigshafen am Rhein, Germany (A. Grau, F.P., C.U.).
Wöhrle JC; Department of Neurology, Community Hospital Klinikum Koblenz, Germany (J.C.W., F.A.).
Alshammari F; Department of Neurology, Community Hospital Klinikum Koblenz, Germany (J.C.W., F.A.).
Horn M; Department of Neurology, Community Hospital Bad Hersfeld, Germany (M. Horn, D.B.).
Bahner D; Department of Neurology, Community Hospital Bad Hersfeld, Germany (M. Horn, D.B.).
Witte OW; Department of Neurology, University of Jena, Germany (O.W.W., A. Günther).
Günther A; Department of Neurology, University of Jena, Germany (O.W.W., A. Günther).
Hamann GF; Department of Neurology and Neurological Rehabilitation, Bezirkskrankenhaus Günzburg, Germany (J.F.H.).
Engelhorn T; Department of Neuroradiology (T.E., H.L., A.D.), University of Erlangen-Nuremberg, Germany.
Lücking H; Department of Neuroradiology (T.E., H.L., A.D.), University of Erlangen-Nuremberg, Germany.
Dörfler A; Department of Neuroradiology (T.E., H.L., A.D.), University of Erlangen-Nuremberg, Germany.
Schwab S; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Huttner HB; From the Department of Neurology (S.T.G., J.B.K., J.A.S., M.I.S., M. Hagen, R.U.K., S. Schwab, H.B.H.), University of Erlangen-Nuremberg, Germany.
Źródło:
Stroke [Stroke] 2019 Jun; Vol. 50 (6), pp. 1392-1402. Date of Electronic Publication: 2019 May 16.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 1998- : Baltimore, Md. : Lippincott Williams & Wilkins
Original Publication: Dallas : American Heart Association
MeSH Terms:
Anticoagulants/*administration & dosage
Cerebral Hemorrhage/*drug therapy
Fibrinolytic Agents/*administration & dosage
Vitamin K/*antagonists & inhibitors
Administration, Oral ; Aged ; Aged, 80 and over ; Cerebral Hemorrhage/diagnostic imaging ; Cerebral Hemorrhage/epidemiology ; Female ; Germany/epidemiology ; Humans ; Male ; Retrospective Studies
Contributed Indexing:
Keywords: Germany; anticoagulants; cerebral hemorrhage; hematoma; prognosis; vitamin K
Molecular Sequence:
ClinicalTrials.gov NCT03093233
Substance Nomenclature:
0 (Anticoagulants)
0 (Fibrinolytic Agents)
12001-79-5 (Vitamin K)
Entry Date(s):
Date Created: 20190517 Date Completed: 20200122 Latest Revision: 20200122
Update Code:
20240104
DOI:
10.1161/STROKEAHA.118.023492
PMID:
31092170
Czasopismo naukowe
Background and Purpose- Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non-vitamin K antagonist (NOAC)-related ICH. Notably, clinical characteristics according to different NOAC agents and dosages are not established. Methods- Multicenter observational cohort study integrating individual patient data of 1328 patients with oral anticoagulation-associated ICH, including 190 NOAC-related ICH patients, recruited from 2011 to 2015 at 19 tertiary centers across Germany. Imaging, clinical characteristics, and 3-months modified Rankin Scale (mRS) outcomes were compared in NOAC- versus VKA-related ICH patients. Propensity score matching was conducted to adjust for clinically relevant differences in baseline parameters. Subgroup analyses were performed regarding NOAC agent, dosing and present clinically relevant anticoagulatory activity (last intake <12h/24h or NOAC level >30 ng/mL). Results- Despite older age in NOAC patients, there were no relevant differences in clinical and hematoma characteristics between NOAC- and VKA-related ICH regarding baseline hematoma volume (median [interquartile range]: NOAC, 14.7 [5.1-42.3] mL versus VKA, 16.4 [5.8-40.6] mL; P=0.33), rate of hematoma expansion (NOAC, 49/146 [33.6%] versus VKA, 235/688 [34.2%]; P=0.89), and the proportion of patients with unfavorable outcome at 3 months (mRS, 4-6: NOAC 126/179 [70.4%] versus VKA 473/682 [69.4%]; P=0.79). Subgroup analyses revealed that NOAC patients with clinically relevant anticoagulatory effect had higher rates of intraventricular hemorrhage (n/N [%]: present 52/109 [47.7%] versus absent 9/35 [25.7%]; P=0.022) and hematoma expansion (present 35/90 [38.9%] versus absent 5/30 [16.7%]; P=0.040), whereas type of NOAC agent or different NOAC-dosing regimens did not result in relevant differences in imaging characteristics or outcome. Conclusions- If effectively anticoagulated, there are no differences in hematoma characteristics and functional outcome among patients with NOAC- or VKA-related ICH. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT03093233.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies